ClinicalTrials.gg
CompletedNCT00710762Updated Aug 15, 2016Results posted

A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer

A Phase 2 interventional study of BIBF1120 and Placebo in Ovarian Neoplasms, sponsored by Boehringer Ingelheim. Completed at 11 sites in United Kingdom. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-15.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
89
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 293 studies in Ovarian Neoplasms with a site in United Kingdom — 54 open to participants now, 85 under way, 25 of them phase 3. Ovarian Neoplasms · United Kingdom.

Enrollment
165th of 249
89 · median 158
Started
2006
with 10 others
Phase 2
73 of 293
7 open now
Registered
58th of 293
by date

Among the 293 studies in Ovarian Neoplasms with a site in United Kingdom, this one is the 165th largest by enrollment of the 249 interventional ones that give a count, is one of 11 that started in 2006, is one of 73 in phase 2, and was the 58th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

54 of the 293 studies in Ovarian Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

49 more — sign in →

All 54 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies in Ovarian Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

The primary objective of this study is to estimate the Progression Free Survival Rates (PFS) of patients with relapsed ovarian cancer after 9 months of continuous treatment with either BIBF 1120 or matching placebo.

03

Conditions studied

  • Ovarian Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients with confirmed advanced ovarian carcinoma, fallopian tube carcinoma or primary peritoneal cancer of serous type with recurrent disease and who responded to 2nd, 3rd or 4th line chemotherapy. Response is defined as either a confirmed decline in CA125 of at least 50% from the pre-treatment value or an Objective Response, i.e. a Partial Response (PR) or Complete Response (CR) according to the criteria in patients with .
  • Treatment-free interval of \< 12 months since commencing prior treatment regimen for ovarian cancer.
  • Full recovery from all therapy related toxicities of previous chemotherapy and or radiotherapy or recovery in as much as no further improvement may be expected by the investigator.
  • Age > 18 years.
  • of at least 3 months.
  • Performance Score \< 2.
  • Adequate hepatic function: total 26µmol/L, and/or AST 1.5x (ULN). , Prothrombin time (PT) and partial thromboplastin time (PTT): maximum 50% deviation from normal limits.
  • Adequate renal function: serum creatinine 1.5 x ULN.
  • (ANC) >1.5 x 109l, > 100 x 109/l, > 9.0 g/dl.
  • Written consistent with ICH-GCP guidelines.
  • Minimum time elapsed since last chemotherapy (including hormonal treatment other than Hormone Replacement Therapy [HRT]) or immunotherapy and the first administration of BIBF 1120 must be more than 4 but less than 8 weeks.

Exclusion criteria

Exclusion Criteria:

  • Serious illness or concomitant non-oncological disease such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the study.
  • Major injuries and/or surgery within past 4 weeks with incomplete wound healing or bone fracture and planned surgical procedures during the study period.
  • to BIBF 1120 or the of the study drug.
  • Significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction within past 9 months, congestive heart failure > II).
  • History of haemorrhagic or thrombotic event in the past 12 months. Known inherited predisposition to bleeds or to thrombosis.
  • Patients who require full-dose anticoagulation.
  • Gastrointestinal disorders or abnormalities that would inhibit absorption of the study drug.
  • or .
  • Treatment with other drugs or participation in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial.
  • Chemo-, radio-, or immunotherapy within the past four weeks prior to treatment with the trial drug.
  • Patients unable to comply with the protocol.
  • Active alcohol or drug abuse.
  • Other documented with the exception of non-melanomatous skin cancer within the past 5 years.
  • Patients who are not clinically sterile.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Intervention model
Parallel assignment
Enrollment
89 participants (actual)

Study arms

  • Experimental
    BIBF1120

    Drug: BIBF1120

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. PFS Rate at 36 Weeks (After 9 Months)

    The rate (probability) of being progression free at Week 36. Progression Free Survival (PFS) was defined according to RECIST version 1.0 from the time of first study drug administration to the first time of either objective tumour progression, the appearance of ≥1 new tumour lesion(s), occurrence or significant progression of malignant ascites, tumour related death, or the time when patients were censored at last known follow up. The rate is the Kaplan-Meier estimated percent probability.

    Time frame: 36 weeks (after 9 months)

Secondary outcomes

  1. PFS Rate at 12 Weeks (After 3 Months) and 24 Weeks ( After 6 Months)

    The rate (probability) of being progression free at Week 12 and Week 24. Progression Free Survival (PFS) was defined according to RECIST version 1.0 from the time of first study drug administration to the first time of either objective tumour progression, the appearance of ≥1 new tumour lesion(s), occurrence or significant progression of malignant ascites, tumour related death, or the time when patients were censored at last known follow up. The rate is the Kaplan-Meier estimated percent probability.

    Time frame: 12 weeks (after 3 months) and 24 weeks ( after 6 months)

  2. Time to Tumour Progression

    Time to Tumour Progression according to RECIST version 1.0 , CA-125 (ovarian tumour marker) levels and RECIST + CA-125 levels. For CA-125, progressive disease was defined on the basis of progressive serial elevations of CA-125 according to the following criteria: Patients with elevated CA-125 pre-treatment and normalisation of CA-125 had to show evidence of CA-125 levels ≥2 x ULN on 2 occasions at least 1 week apart. or Patients with elevated CA-125 pre-treatment that never normalised had to show evidence of CA-125 levels ≥2 x the nadir value on 2 occasions at least 1 week apart. or Patients with CA-125 in the normal range pre-treatment had to show evidence of CA-125 levels ≥2 x ULN on 2 occasions at least 1 week apart. Composite (RECIST+CA-125) endpoint is the RECIST progressive disease (PD) if it occurred or the CA-125 PD if it occurred in the absence of RECIST PD.

    Time frame: 9 months

  3. Time to Death

    This end point was not determined as no patients died during the trial.

    Time frame: 9 months

  4. Incidence and Intensity of Adverse Events With Grading According CTCAE

    Incidence and intensity of Adverse Events with grading according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0).

    Time frame: First drug administration until 28 days after last drug administration,up until 309 days

  5. Clinical Relevant Abnormalities for Laboratory Parameters

    Clinical Relevant Abnormalities for laboratory parameters. Any new or clinically relevant worsening of baseline conditions was reported as Adverse Events.

    Time frame: First drug administration until 28 days after last drug administration, up until 309 days

07

Results

Posted Dec 4, 2014
Limitations and caveats
Data from all randomised patients collected upto NOV'08 were included in all above sections,unless stated otherwise.5 patients continued on BIBF1120 after database lock(DBL)-NOV'08 upto Mar'14,but due to limited data no further analyses were done.

Participant flow

Participant flow — Overall Study
MilestoneNintedanibPlacebo
Started4440
Completed50
Not completed3940
Withdrew: Progressive disease2730
Withdrew: Adverse event other disease worsening21
Withdrew: Other adverse event77
Withdrew: Lost to follow-up10
Withdrew: Reason other than listed above22

Outcome measures

PrimaryPFS Rate at 36 Weeks (After 9 Months)

The rate (probability) of being progression free at Week 36. Progression Free Survival (PFS) was defined according to RECIST version 1.0 from the time of first study drug administration to the first time of either objective tumour progression, the appearance of ≥1 new tumour lesion(s), occurrence or significant progression of malignant ascites, tumour related death, or the time when patients were censored at last known follow up. The rate is the Kaplan-Meier estimated percent probability.

Time frame:
36 weeks (after 9 months)
Reported as:
Number · percent probability of PFS
PFS Rate at 36 Weeks (After 9 Months)
percent probability of PFSNintedanibPlacebo
PFS Rate at 36 Weeks (After 9 Months)15.6 (3.8 to 27.3)2.9 (0.0 to 8.4)
SecondaryPFS Rate at 12 Weeks (After 3 Months) and 24 Weeks ( After 6 Months)

The rate (probability) of being progression free at Week 12 and Week 24. Progression Free Survival (PFS) was defined according to RECIST version 1.0 from the time of first study drug administration to the first time of either objective tumour progression, the appearance of ≥1 new tumour lesion(s), occurrence or significant progression of malignant ascites, tumour related death, or the time when patients were censored at last known follow up. The rate is the Kaplan-Meier estimated percent probability.

Time frame:
12 weeks (after 3 months) and 24 weeks ( after 6 months)
Reported as:
Number · percent probability of PFS
PFS Rate at 12 Weeks (After 3 Months) and 24 Weeks ( After 6 Months)
percent probability of PFSNintedanibPlacebo
at 24 weeks ( after 6 months)26.7 (12.5 to 40.8)17.3 (5.2 to 29.4)
at 12 weeks (after 3 months)45.3 (29.5 to 61.2)46.2 (30.5 to 61.8)
SecondaryTime to Tumour Progression

Time to Tumour Progression according to RECIST version 1.0 , CA-125 (ovarian tumour marker) levels and RECIST + CA-125 levels. For CA-125, progressive disease was defined on the basis of progressive serial elevations of CA-125 according to the following criteria: Patients with elevated CA-125 pre-treatment and normalisation of CA-125 had to show evidence of CA-125 levels ≥2 x ULN on 2 occasions at least 1 week apart. or Patients with elevated CA-125 pre-treatment that never normalised had to show evidence of CA-125 levels ≥2 x the nadir value on 2 occasions at least 1 week apart. or Patients with CA-125 in the normal range pre-treatment had to show evidence of CA-125 levels ≥2 x ULN on 2 occasions at least 1 week apart. Composite (RECIST+CA-125) endpoint is the RECIST progressive disease (PD) if it occurred or the CA-125 PD if it occurred in the absence of RECIST PD.

Time frame:
9 months
Reported as:
Median · days
Time to Tumour Progression
daysNintedanibPlacebo
according to RECIST and CA-12583.00 (78.0 to 149.0)84.00 (78.0 to 87.0)
according to CA-12585.00 (79.0 to 149.0)86.00 (67.0 to 113.0)
according to RECIST143.0 (82.0 to 175.0)85.0 (78.0 to 89.0)
SecondaryTime to Death

This end point was not determined as no patients died during the trial.

Time frame:
9 months

No measurements were reported for this outcome.

SecondaryIncidence and Intensity of Adverse Events With Grading According CTCAE

Incidence and intensity of Adverse Events with grading according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0).

Time frame:
First drug administration until 28 days after last drug administration,up until 309 days
Reported as:
Number · percentage of participants
Incidence and Intensity of Adverse Events With Grading According CTCAE
percentage of participantsNintedanibPlacebo
CTCAE grade 12.325.0
CTCAE grade 234.942.5
CTCAE grade 353.525.0
CTCAE grade 47.02.5
CTCAE grade 50.00.0
SecondaryClinical Relevant Abnormalities for Laboratory Parameters

Clinical Relevant Abnormalities for laboratory parameters. Any new or clinically relevant worsening of baseline conditions was reported as Adverse Events.

Time frame:
First drug administration until 28 days after last drug administration, up until 309 days
Reported as:
Number · Percentage of participants
Clinical Relevant Abnormalities for Laboratory Parameters
Percentage of participantsNintedanibPlacebo
Alanine aminotransferase increased37.27.5
Gamma-glutamyltransferase increased30.22.5
Aspartate aminotransferase increased25.62.5
Blood alkaline phosphatase increased7.05.0
Blood lactate dehydrogenase increased4.70.0
Blood alkaline phosphatase0.02.5
Blood alkaline phosphatase abnormal2.32.5
Lymphocyte count decreased0.02.5
Vitamin B12 decreased0.02.5
Alanine aminotransferase abnormal2.30.0
Blood lactate dehydrogenase abnormal2.30.0
Gamma-glutamyltransferase abnormal2.30.0
Neutrophil count decreased2.30.0
White blood cells urine positive2.30.0
Blood pressure increased0.02.5
Electrocardiogram T wave amplitude decreased0.02.5
Liver function test abnormal2.30.0

Adverse events

Collected over First drug administration until 28 days after last drug administration, up until 309 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nintedanib—14/43 (32.6%)42/43 (97.7%)
Placebo—10/40 (25%)37/40 (92.5%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventNintedanibPlacebo
VomitingGastrointestinal disorders10/430/40
AscitesGastrointestinal disorders6/435/40
Abdominal painGastrointestinal disorders4/432/40
DiarrhoeaGastrointestinal disorders3/430/40
Intestinal obstructionGastrointestinal disorders2/431/40
PancytopeniaBlood and lymphatic system disorders0/431/40
Small intestinal obstructionGastrointestinal disorders1/431/40
Catheter related infectionInfections and infestations0/431/40
DehydrationMetabolism and nutrition disorders0/431/40
Lung neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/431/40
Most frequent other events
Showing 10 of 39
Most frequent other events
EventNintedanibPlacebo
DiarrhoeaGastrointestinal disorders33/4314/40
NauseaGastrointestinal disorders32/4313/40
Abdominal painGastrointestinal disorders23/4315/40
VomitingGastrointestinal disorders23/439/40
Alanine aminotransferase increasedInvestigations16/433/40
FatigueGeneral disorders12/4311/40
Gamma-glutamyltransferase increasedInvestigations12/431/40
ConstipationGastrointestinal disorders9/4311/40
AnorexiaMetabolism and nutrition disorders11/436/40
Aspartate aminotransferase increasedInvestigations10/431/40

Baseline characteristics

Treated set consist of all patients who received at least 1 dose of nintedanib or placebo. Note: 43 patients were included in the analyses instead of 44 patients in nintedanib arm as one patient was excluded after drug administration due to important protocol violation.

Age, Continuous
Age, Continuous(years)NintedanibPlaceboTotal
Mean58.4 ± 9.561.3 ± 9.159.8 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)NintedanibPlaceboTotal
Female434083
Male000
08

Study locations

11 sites
  • 1199.9.4413 Boehringer Ingelheim Investigational Site
    Burton on Trent, United Kingdom
  • 1199.9.4412 Boehringer Ingelheim Investigational Site
    Cambridge, United Kingdom
  • 1199.9.4407 Boehringer Ingelheim Investigational Site
    Creigiau, Cardiff, United Kingdom
  • 1199.9.4410 St James's University Hospital
    Leeds, United Kingdom
  • 1199.9.4401 Boehringer Ingelheim Investigational Site
    London, United Kingdom
  • 1199.9.4404 Boehringer Ingelheim Investigational Site
    London, United Kingdom
  • 1199.9.4409 Boehringer Ingelheim Investigational Site
    London, United Kingdom
  • 1199.9.4411 Boehringer Ingelheim Investigational Site
    London, United Kingdom
  • 1199.9.4406 Boehringer Ingelheim Investigational Site
    Manchester, United Kingdom
  • 1199.9.4402 Boehringer Ingelheim Investigational Site
    Northwood, United Kingdom
  • 1199.9.4405 Boehringer Ingelheim Investigational Site
    Sutton, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006, a primary completion of Sep 2008 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 6 years 3 months after primary completion. A results delay was requested in May 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2008
First posted
Jul 4, 2008
Start
Mar 2006
Primary completionActual
Sep 2008
CompletionActual
Mar 2014
Results delay requested
May 6, 2014
Results first posted
Dec 4, 2014
Last update
Aug 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00710762
Responsible party
Sponsor
First posted
Jul 4, 2008
Start date
Mar 2006
Primary completion
Sep 2008
Completion
Mar 2014
Results posted
Dec 4, 2014
Last update
Aug 15, 2016

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion